Travere Therapeutics, Inc. — Form 8-K
Filed September 21, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Eric Dube, Ph.D. voluntarily resigned as President and CEO effective December 1, 2026, with employment terminating February 15, 2027. Bradley Campbell was hired as the new President and CEO, effective December 1, 2026, with a base salary of $1,000,000 annually, target bonus of 85% ($850,000), and initial equity grants valued at approximately $16.5 million ($8.25M stock options + $8.25M time-based RSUs), plus a $3.75M performance-based RSU award in early 2027. Dube receives transition assistance payments and consulting engagement through February 15, 2027, with up to 18 months of COBRA premium coverage and equity acceleration provisions if consulting is terminated.
Why this rating
CEO transition with planned succession is material but not surprising; Campbell's $16.5M equity grant is ~1.3% of $1.3B market cap; Dube's departure without major financial severance reduces disruption risk.
Price action (we called it neutral)
before filing · preread $62.86 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.